| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cholesterol, LDL | 13 | 2019 | 499 | 2.08 | Why? |
| Anticholesteremic Agents | 10 | 2019 | 186 | 1.78 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 15 | 2019 | 1510 | 1.75 | Why? |
| Physical Endurance | 4 | 2020 | 107 | 1.56 | Why? |
| Telomerase | 2 | 2019 | 45 | 1.55 | Why? |
| Heart Failure | 12 | 2019 | 6638 | 1.27 | Why? |
| Resistance Training | 2 | 2019 | 273 | 1.23 | Why? |
| Ventricular Remodeling | 2 | 2019 | 349 | 1.16 | Why? |
| Dyslipidemias | 7 | 2019 | 791 | 1.11 | Why? |
| Mitral Valve Insufficiency | 2 | 2018 | 302 | 1.06 | Why? |
| Lipoproteins, LDL | 3 | 2019 | 115 | 1.04 | Why? |
| Hypercholesterolemia | 3 | 2019 | 175 | 1.00 | Why? |
| Cardiovascular Diseases | 16 | 2019 | 11497 | 0.95 | Why? |
| Hyperlipoproteinemia Type II | 3 | 2018 | 123 | 0.92 | Why? |
| Atherosclerosis | 4 | 2017 | 768 | 0.91 | Why? |
| Ventricular Function, Left | 4 | 2020 | 1555 | 0.87 | Why? |
| Exercise Tolerance | 3 | 2020 | 634 | 0.86 | Why? |
| Receptors, Mineralocorticoid | 1 | 2019 | 15 | 0.81 | Why? |
| Naphthyridines | 1 | 2019 | 48 | 0.80 | Why? |
| Receptors, LDL | 2 | 2018 | 42 | 0.79 | Why? |
| Atrial Remodeling | 1 | 2019 | 31 | 0.78 | Why? |
| Phosphatidylethanolamine Binding Protein | 1 | 2018 | 2 | 0.78 | Why? |
| Cardiovascular Agents | 4 | 2019 | 663 | 0.78 | Why? |
| Xanthomatosis | 1 | 2018 | 11 | 0.75 | Why? |
| Telomere Homeostasis | 1 | 2019 | 52 | 0.75 | Why? |
| Apoptosis | 3 | 2018 | 2335 | 0.75 | Why? |
| Lipid Metabolism | 3 | 2017 | 572 | 0.73 | Why? |
| Coumaric Acids | 1 | 2017 | 11 | 0.72 | Why? |
| Interdisciplinary Studies | 1 | 2018 | 95 | 0.71 | Why? |
| Fibroblasts | 3 | 2019 | 839 | 0.71 | Why? |
| Palmitic Acid | 1 | 2017 | 28 | 0.71 | Why? |
| Adrenergic beta-Antagonists | 2 | 2019 | 465 | 0.70 | Why? |
| Mineralocorticoid Receptor Antagonists | 1 | 2019 | 203 | 0.68 | Why? |
| AMP-Activated Protein Kinases | 1 | 2017 | 93 | 0.66 | Why? |
| Cell-Derived Microparticles | 1 | 2017 | 134 | 0.64 | Why? |
| Oryza | 1 | 2017 | 86 | 0.63 | Why? |
| Cholesterol, HDL | 4 | 2019 | 439 | 0.63 | Why? |
| Running | 1 | 2017 | 153 | 0.59 | Why? |
| Coronary Thrombosis | 1 | 2020 | 433 | 0.58 | Why? |
| Myocytes, Cardiac | 3 | 2019 | 804 | 0.57 | Why? |
| Comprehension | 1 | 2017 | 259 | 0.55 | Why? |
| Myocardium | 4 | 2019 | 2323 | 0.55 | Why? |
| Medication Adherence | 3 | 2019 | 1270 | 0.55 | Why? |
| Coronary Disease | 2 | 2017 | 645 | 0.55 | Why? |
| Mitral Valve | 1 | 2018 | 342 | 0.54 | Why? |
| Physical Fitness | 1 | 2017 | 334 | 0.54 | Why? |
| Cardiac Catheterization | 2 | 2018 | 882 | 0.54 | Why? |
| Echocardiography | 5 | 2020 | 3661 | 0.53 | Why? |
| Takotsubo Cardiomyopathy | 1 | 2020 | 453 | 0.53 | Why? |
| Stroke Volume | 3 | 2019 | 2153 | 0.52 | Why? |
| Ventricular Dysfunction, Left | 2 | 2020 | 993 | 0.51 | Why? |
| Cardiovascular System | 2 | 2018 | 750 | 0.50 | Why? |
| Plaque, Atherosclerotic | 1 | 2017 | 423 | 0.48 | Why? |
| Cardiomyopathies | 2 | 2018 | 997 | 0.46 | Why? |
| Myalgia | 1 | 2017 | 1015 | 0.46 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2018 | 552 | 0.45 | Why? |
| Cognition | 2 | 2017 | 1394 | 0.45 | Why? |
| Fibrosis | 4 | 2019 | 800 | 0.45 | Why? |
| Oxidative Stress | 4 | 2019 | 2050 | 0.45 | Why? |
| Muscular Diseases | 1 | 2017 | 392 | 0.45 | Why? |
| Cholesterol | 4 | 2019 | 660 | 0.44 | Why? |
| Proprotein Convertase 9 | 5 | 2019 | 141 | 0.43 | Why? |
| Cardiology | 3 | 2020 | 2873 | 0.41 | Why? |
| Risk Reduction Behavior | 1 | 2017 | 946 | 0.41 | Why? |
| Mitochondria | 1 | 2017 | 857 | 0.41 | Why? |
| Apolipoproteins E | 3 | 2017 | 170 | 0.40 | Why? |
| Natriuretic Peptide, Brain | 1 | 2017 | 1215 | 0.39 | Why? |
| Hyperlipidemias | 4 | 2019 | 290 | 0.38 | Why? |
| RNA, Viral | 4 | 2020 | 32276 | 0.36 | Why? |
| Hydroxymethylglutaryl CoA Reductases | 2 | 2017 | 8 | 0.36 | Why? |
| Diabetes Mellitus, Type 2 | 3 | 2018 | 6166 | 0.35 | Why? |
| Subtilisins | 2 | 2017 | 29 | 0.35 | Why? |
| Telomere | 2 | 2019 | 146 | 0.34 | Why? |
| Atrial Fibrillation | 5 | 2021 | 2320 | 0.33 | Why? |
| Brain Ischemia | 4 | 2021 | 2813 | 0.33 | Why? |
| Fatty Acids | 2 | 2019 | 238 | 0.33 | Why? |
| Endothelial Cells | 1 | 2017 | 2048 | 0.33 | Why? |
| Rats, Sprague-Dawley | 3 | 2019 | 987 | 0.33 | Why? |
| Blood Platelets | 1 | 2017 | 1704 | 0.31 | Why? |
| Peptide Fragments | 1 | 2017 | 2075 | 0.31 | Why? |
| Hemodynamics | 3 | 2019 | 1562 | 0.30 | Why? |
| Serine Proteinase Inhibitors | 2 | 2019 | 341 | 0.29 | Why? |
| Ezetimibe | 3 | 2019 | 50 | 0.29 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2019 | 3892 | 0.29 | Why? |
| Magnetic Resonance Imaging, Cine | 2 | 2020 | 669 | 0.27 | Why? |
| Cells, Cultured | 4 | 2019 | 5835 | 0.27 | Why? |
| Mice, Knockout | 3 | 2018 | 1815 | 0.26 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 5277 | 0.26 | Why? |
| Humans | 71 | 2021 | 930598 | 0.26 | Why? |
| Dyspnea | 1 | 2017 | 3847 | 0.25 | Why? |
| Mice, Inbred C57BL | 4 | 2018 | 5542 | 0.25 | Why? |
| Secondary Prevention | 2 | 2019 | 762 | 0.25 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.25 | Why? |
| Biomarkers | 14 | 2019 | 23361 | 0.24 | Why? |
| Exercise | 2 | 2020 | 6771 | 0.24 | Why? |
| Prospective Studies | 12 | 2020 | 43301 | 0.24 | Why? |
| Pravastatin | 1 | 2001 | 10 | 0.23 | Why? |
| Germany | 6 | 2019 | 9196 | 0.22 | Why? |
| Osteoporosis, Postmenopausal | 1 | 2001 | 75 | 0.21 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.21 | Why? |
| Dicarboxylic Acids | 1 | 2019 | 12 | 0.20 | Why? |
| Oxygen Consumption | 3 | 2020 | 711 | 0.20 | Why? |
| Apolipoprotein B-100 | 1 | 2019 | 18 | 0.20 | Why? |
| Cross-Over Studies | 2 | 2020 | 867 | 0.20 | Why? |
| Lipoproteins, VLDL | 1 | 2019 | 8 | 0.20 | Why? |
| Connective Tissue Growth Factor | 1 | 2019 | 8 | 0.20 | Why? |
| rac1 GTP-Binding Protein | 1 | 2019 | 32 | 0.20 | Why? |
| NADP Transhydrogenase, AB-Specific | 1 | 2018 | 1 | 0.20 | Why? |
| Risk Factors | 17 | 2021 | 71621 | 0.20 | Why? |
| Aorta | 3 | 2019 | 355 | 0.19 | Why? |
| Mice, Inbred DBA | 1 | 2018 | 56 | 0.19 | Why? |
| Male | 35 | 2021 | 367725 | 0.19 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.19 | Why? |
| Physical Conditioning, Human | 1 | 2019 | 57 | 0.19 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.18 | Why? |
| Neuropeptides | 1 | 2019 | 91 | 0.18 | Why? |
| Echocardiography, Doppler, Color | 1 | 2019 | 114 | 0.18 | Why? |
| Proto-Oncogene Proteins c-kit | 1 | 2018 | 59 | 0.18 | Why? |
| Diet Therapy | 1 | 2019 | 66 | 0.18 | Why? |
| Vasodilation | 2 | 2019 | 258 | 0.18 | Why? |
| Animals, Newborn | 1 | 2019 | 350 | 0.18 | Why? |
| Practice Guidelines as Topic | 3 | 2018 | 15421 | 0.18 | Why? |
| Aminoimidazole Carboxamide | 1 | 2017 | 6 | 0.18 | Why? |
| Life Style | 3 | 2019 | 2708 | 0.18 | Why? |
| Cholesterol Ester Transfer Proteins | 1 | 2017 | 8 | 0.18 | Why? |
| Organelle Biogenesis | 1 | 2017 | 15 | 0.18 | Why? |
| Leukocyte Common Antigens | 1 | 2018 | 101 | 0.18 | Why? |
| Apolipoproteins B | 1 | 2017 | 47 | 0.18 | Why? |
| Fibronectins | 1 | 2018 | 92 | 0.18 | Why? |
| Proprotein Convertases | 1 | 2017 | 28 | 0.18 | Why? |
| Postmenopause | 1 | 2019 | 160 | 0.17 | Why? |
| Alternative Splicing | 1 | 2018 | 82 | 0.17 | Why? |
| Athletic Performance | 1 | 2020 | 208 | 0.17 | Why? |
| Masks | 1 | 2020 | 8528 | 0.17 | Why? |
| Genetic Pleiotropy | 1 | 2017 | 13 | 0.17 | Why? |
| Mitochondrial Proteins | 1 | 2018 | 152 | 0.17 | Why? |
| Electrocardiography, Ambulatory | 2 | 2018 | 204 | 0.17 | Why? |
| Homozygote | 1 | 2018 | 230 | 0.17 | Why? |
| Electrocardiography | 5 | 2021 | 3957 | 0.17 | Why? |
| Monitoring, Physiologic | 2 | 2021 | 1956 | 0.17 | Why? |
| Atrial Appendage | 1 | 2019 | 120 | 0.17 | Why? |
| Treatment Outcome | 12 | 2019 | 51732 | 0.16 | Why? |
| Ribonucleotides | 1 | 2017 | 96 | 0.16 | Why? |
| Cardiomegaly | 1 | 2017 | 96 | 0.16 | Why? |
| Echocardiography, Three-Dimensional | 1 | 2018 | 135 | 0.16 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| Cardiopulmonary Bypass | 1 | 2018 | 158 | 0.16 | Why? |
| Quantitative Trait Loci | 1 | 2018 | 340 | 0.16 | Why? |
| Obesity | 3 | 2019 | 7388 | 0.16 | Why? |
| Transforming Growth Factor beta | 1 | 2019 | 363 | 0.16 | Why? |
| Animals | 11 | 2019 | 78931 | 0.16 | Why? |
| Diet, High-Fat | 1 | 2017 | 161 | 0.16 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.16 | Why? |
| Lipoprotein(a) | 1 | 2017 | 92 | 0.16 | Why? |
| Gene Deletion | 1 | 2018 | 430 | 0.16 | Why? |
| Triglycerides | 1 | 2019 | 478 | 0.15 | Why? |
| Femoral Artery | 1 | 2018 | 213 | 0.15 | Why? |
| Biological Availability | 1 | 2017 | 388 | 0.15 | Why? |
| Blood Component Removal | 1 | 2018 | 175 | 0.15 | Why? |
| Female | 31 | 2021 | 380317 | 0.15 | Why? |
| Heart Rate | 2 | 2019 | 1527 | 0.15 | Why? |
| Drug Utilization | 1 | 2021 | 619 | 0.15 | Why? |
| Vascular Stiffness | 1 | 2019 | 264 | 0.15 | Why? |
| Body Mass Index | 4 | 2019 | 4306 | 0.15 | Why? |
| Lipoproteins, HDL | 1 | 2017 | 154 | 0.15 | Why? |
| Drug Costs | 1 | 2019 | 313 | 0.15 | Why? |
| Echocardiography, Transesophageal | 1 | 2019 | 447 | 0.15 | Why? |
| Cataract | 1 | 2018 | 186 | 0.14 | Why? |
| Diabetic Angiopathies | 1 | 2017 | 146 | 0.14 | Why? |
| Cardiorespiratory Fitness | 1 | 2019 | 313 | 0.14 | Why? |
| Time Factors | 11 | 2019 | 31397 | 0.14 | Why? |
| Diabetes Mellitus | 1 | 2017 | 8207 | 0.14 | Why? |
| Polypharmacy | 1 | 2017 | 347 | 0.14 | Why? |
| Endothelium, Vascular | 3 | 2017 | 1751 | 0.14 | Why? |
| Autonomic Denervation | 1 | 2013 | 2 | 0.14 | Why? |
| NF-E2-Related Factor 2 | 1 | 2018 | 373 | 0.14 | Why? |
| Cell Movement | 1 | 2018 | 695 | 0.14 | Why? |
| Rats | 2 | 2019 | 2764 | 0.14 | Why? |
| Homeostasis | 1 | 2018 | 582 | 0.14 | Why? |
| Arginine | 1 | 2017 | 377 | 0.14 | Why? |
| Sarcoidosis | 1 | 2018 | 271 | 0.14 | Why? |
| Drug Substitution | 1 | 2017 | 385 | 0.14 | Why? |
| Coronary Artery Disease | 2 | 2019 | 2570 | 0.14 | Why? |
| Cardiotonic Agents | 1 | 2017 | 418 | 0.13 | Why? |
| Expert Testimony | 1 | 2018 | 658 | 0.13 | Why? |
| Adipose Tissue | 1 | 2019 | 612 | 0.13 | Why? |
| Evidence-Based Medicine | 2 | 2017 | 3228 | 0.13 | Why? |
| Glucose | 1 | 2018 | 573 | 0.13 | Why? |
| Genetic Association Studies | 1 | 2017 | 559 | 0.13 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.13 | Why? |
| Genetic Testing | 1 | 2017 | 395 | 0.13 | Why? |
| Biological Evolution | 1 | 2019 | 641 | 0.13 | Why? |
| Receptors, Immunologic | 1 | 2017 | 555 | 0.13 | Why? |
| Chemical and Drug Induced Liver Injury | 1 | 2018 | 451 | 0.13 | Why? |
| Genetic Variation | 2 | 2017 | 3919 | 0.13 | Why? |
| Cognition Disorders | 1 | 2018 | 574 | 0.12 | Why? |
| Phenotype | 3 | 2018 | 4037 | 0.12 | Why? |
| Cattle | 1 | 2017 | 1336 | 0.12 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.12 | Why? |
| Lipids | 2 | 2017 | 1079 | 0.12 | Why? |
| Databases, Factual | 2 | 2018 | 6248 | 0.12 | Why? |
| Antigens, CD | 1 | 2017 | 984 | 0.12 | Why? |
| Immunoglobulins | 1 | 2017 | 811 | 0.12 | Why? |
| Healthy Lifestyle | 1 | 2017 | 447 | 0.12 | Why? |
| Anti-Arrhythmia Agents | 2 | 2017 | 325 | 0.12 | Why? |
| Mice, Transgenic | 1 | 2019 | 2739 | 0.12 | Why? |
| Aged | 18 | 2021 | 215776 | 0.12 | Why? |
| Disease Models, Animal | 3 | 2019 | 10998 | 0.11 | Why? |
| Vaccines, Subunit | 1 | 2017 | 1088 | 0.11 | Why? |
| Educational Status | 1 | 2017 | 1451 | 0.11 | Why? |
| Kidney | 2 | 2017 | 3648 | 0.11 | Why? |
| Impotence, Vasculogenic | 1 | 2010 | 3 | 0.11 | Why? |
| Lung | 1 | 2020 | 31049 | 0.11 | Why? |
| Societies, Medical | 2 | 2017 | 6907 | 0.11 | Why? |
| Myocardial Infarction | 1 | 2007 | 3361 | 0.11 | Why? |
| Cell Proliferation | 1 | 2018 | 1973 | 0.11 | Why? |
| Drug Combinations | 2 | 2019 | 3852 | 0.11 | Why? |
| Environment | 1 | 2017 | 769 | 0.10 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.10 | Why? |
| Heart | 1 | 2020 | 1791 | 0.10 | Why? |
| Cerebral Hemorrhage | 1 | 2018 | 820 | 0.10 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.10 | Why? |
| Benzazepines | 1 | 2010 | 49 | 0.10 | Why? |
| RNA | 1 | 2018 | 1278 | 0.10 | Why? |
| Penile Erection | 1 | 2010 | 58 | 0.10 | Why? |
| Mice | 3 | 2019 | 21357 | 0.10 | Why? |
| Penis | 1 | 2010 | 101 | 0.10 | Why? |
| Self Care | 1 | 2017 | 918 | 0.10 | Why? |
| Exercise Therapy | 1 | 2017 | 976 | 0.09 | Why? |
| Antibodies, Monoclonal | 2 | 2019 | 8041 | 0.09 | Why? |
| Feasibility Studies | 1 | 2018 | 3467 | 0.09 | Why? |
| Down-Regulation | 3 | 2019 | 1416 | 0.09 | Why? |
| Smoking Cessation | 1 | 2017 | 826 | 0.09 | Why? |
| Chronic Disease | 3 | 2019 | 5139 | 0.09 | Why? |
| Waist-Hip Ratio | 1 | 2007 | 50 | 0.09 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.08 | Why? |
| Recovery of Function | 1 | 2017 | 2461 | 0.08 | Why? |
| Kidney Diseases | 1 | 2018 | 1434 | 0.08 | Why? |
| Internal-External Control | 1 | 2007 | 65 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.08 | Why? |
| Risk Assessment | 6 | 2019 | 25439 | 0.08 | Why? |
| Cognitive Dysfunction | 1 | 2017 | 1389 | 0.08 | Why? |
| Consensus | 2 | 2017 | 6345 | 0.08 | Why? |
| Comorbidity | 4 | 2019 | 34796 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2019 | 1996 | 0.07 | Why? |
| Arrhythmias, Cardiac | 1 | 2019 | 2510 | 0.07 | Why? |
| Prognosis | 6 | 2019 | 32490 | 0.07 | Why? |
| Inflammation | 2 | 2018 | 13255 | 0.07 | Why? |
| Risk | 1 | 2017 | 5288 | 0.07 | Why? |
| Signal Transduction | 2 | 2019 | 7207 | 0.07 | Why? |
| Blood Pressure | 2 | 2013 | 2198 | 0.07 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.07 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.07 | Why? |
| Electronic Health Records | 1 | 2017 | 3492 | 0.07 | Why? |
| Cross-Sectional Studies | 4 | 2017 | 53120 | 0.07 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.07 | Why? |
| Hypertension | 2 | 2017 | 8895 | 0.06 | Why? |
| Europe | 2 | 2017 | 12702 | 0.06 | Why? |
| Stress, Psychological | 1 | 2007 | 10231 | 0.06 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.06 | Why? |
| Reproducibility of Results | 2 | 2017 | 11304 | 0.06 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2019 | 9335 | 0.06 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.06 | Why? |
| Liver | 1 | 2017 | 4007 | 0.06 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.06 | Why? |
| Age Factors | 2 | 2017 | 21039 | 0.06 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.06 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.06 | Why? |
| Adult | 7 | 2020 | 244371 | 0.05 | Why? |
| Quality of Life | 2 | 2019 | 9820 | 0.05 | Why? |
| Brain | 1 | 2017 | 5133 | 0.05 | Why? |
| Vitamin D Deficiency | 1 | 2013 | 1782 | 0.05 | Why? |
| Fibrillar Collagens | 1 | 2019 | 6 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| Sitosterols | 1 | 2018 | 7 | 0.05 | Why? |
| Heredity | 1 | 2018 | 37 | 0.05 | Why? |
| Prevalence | 2 | 2019 | 25773 | 0.05 | Why? |
| Depression | 2 | 2017 | 14116 | 0.05 | Why? |
| Spliceosomes | 1 | 2018 | 15 | 0.05 | Why? |
| Viroids | 1 | 2018 | 4 | 0.05 | Why? |
| Paracrine Communication | 1 | 2019 | 73 | 0.05 | Why? |
| Genetic Predisposition to Disease | 3 | 2018 | 4027 | 0.05 | Why? |
| Brachial Artery | 1 | 2019 | 107 | 0.05 | Why? |
| Introns | 1 | 2018 | 112 | 0.04 | Why? |
| Pulse Wave Analysis | 1 | 2019 | 221 | 0.04 | Why? |
| Arteriosclerosis | 1 | 1997 | 50 | 0.04 | Why? |
| Tachycardia | 1 | 2019 | 239 | 0.04 | Why? |
| Vitamin D | 1 | 2013 | 2904 | 0.04 | Why? |
| Myocardial Contraction | 1 | 2019 | 123 | 0.04 | Why? |
| Double-Blind Method | 2 | 2019 | 5988 | 0.04 | Why? |
| RNA, Bacterial | 1 | 2018 | 116 | 0.04 | Why? |
| Cell Count | 1 | 2018 | 228 | 0.04 | Why? |
| Exons | 1 | 2018 | 158 | 0.04 | Why? |
| Arterial Pressure | 1 | 2019 | 208 | 0.04 | Why? |
| Pedigree | 1 | 2018 | 502 | 0.04 | Why? |
| Markov Chains | 1 | 2019 | 502 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Cost Savings | 1 | 2019 | 296 | 0.04 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.04 | Why? |
| Tablets | 1 | 2017 | 219 | 0.04 | Why? |
| Heart Conduction System | 1 | 2019 | 266 | 0.04 | Why? |
| Quality-Adjusted Life Years | 1 | 2019 | 511 | 0.04 | Why? |
| Models, Economic | 1 | 2019 | 316 | 0.04 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.04 | Why? |
| Genetic Markers | 1 | 2017 | 318 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| Endothelium | 1 | 2019 | 460 | 0.04 | Why? |
| Models, Genetic | 1 | 2018 | 434 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2019 | 782 | 0.04 | Why? |
| Diuretics | 1 | 2017 | 326 | 0.04 | Why? |
| Mendelian Randomization Analysis | 1 | 2017 | 317 | 0.04 | Why? |
| Stroke | 1 | 2018 | 8839 | 0.04 | Why? |
| Hypolipidemic Agents | 1 | 2017 | 208 | 0.04 | Why? |
| Heart Valve Diseases | 1 | 2019 | 355 | 0.03 | Why? |
| Cerebral Infarction | 1 | 1997 | 245 | 0.03 | Why? |
| Nucleic Acid Conformation | 1 | 2018 | 621 | 0.03 | Why? |
| Particle Size | 1 | 2019 | 1052 | 0.03 | Why? |
| Epidemiologic Methods | 1 | 2017 | 392 | 0.03 | Why? |
| Predictive Value of Tests | 2 | 2020 | 9537 | 0.03 | Why? |
| Smoking | 1 | 2007 | 3358 | 0.03 | Why? |
| Overweight | 1 | 2019 | 916 | 0.03 | Why? |
| Antihypertensive Agents | 2 | 2017 | 1962 | 0.03 | Why? |
| RNA, Long Noncoding | 1 | 2018 | 408 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2019 | 1136 | 0.03 | Why? |
| Nervous System Diseases | 1 | 2011 | 4092 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.03 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.03 | Why? |
| Vaccination | 1 | 2017 | 19050 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2018 | 25144 | 0.03 | Why? |
| Cholesterol, Dietary | 1 | 2010 | 8 | 0.03 | Why? |
| Drug Resistance | 1 | 2013 | 395 | 0.03 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.03 | Why? |
| Superoxides | 1 | 2010 | 36 | 0.03 | Why? |
| Myocardial Ischemia | 1 | 1997 | 781 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.03 | Why? |
| Nitric Oxide Synthase Type III | 1 | 2010 | 87 | 0.03 | Why? |
| Heart Ventricles | 1 | 2019 | 1139 | 0.03 | Why? |
| Clinical Trials as Topic | 2 | 2017 | 7330 | 0.02 | Why? |
| Retrospective Studies | 2 | 2019 | 105322 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2019 | 2259 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Child | 1 | 2018 | 70012 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| Program Evaluation | 1 | 2017 | 1929 | 0.02 | Why? |
| Collagen | 1 | 2010 | 222 | 0.02 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.02 | Why? |
| Vasodilator Agents | 1 | 2010 | 344 | 0.02 | Why? |
| Enzyme Inhibitors | 1 | 2017 | 1881 | 0.02 | Why? |
| Patient Compliance | 1 | 2015 | 1468 | 0.02 | Why? |
| Cause of Death | 1 | 2019 | 4823 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2019 | 9893 | 0.02 | Why? |
| Acute Disease | 1 | 2015 | 6029 | 0.02 | Why? |
| Serine Endopeptidases | 1 | 2018 | 4606 | 0.01 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.01 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.01 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.01 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Dose-Response Relationship, Drug | 1 | 2010 | 3776 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Length of Stay | 1 | 2015 | 11042 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Anticoagulants | 1 | 2015 | 9563 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| United States | 1 | 2019 | 46150 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.01 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |